Table 1:
Summary of Systematic Reviews of Vertebral Augmentation for Cancer-Related Vertebral Compression Fractures
| Author, Year | Review Type | Vertebral Augmentation Intervention | Vertebral Fracture Etiology | Review Period | Reports Reviewed/Citations Identified | Review Objective |
|---|---|---|---|---|---|---|
| Bouza et al, 200635 | SR and MA | KP | Any pathology | Inception to October 2004 | 26/79 | To evaluate the safety and effectiveness of KP for VCFs |
| Bouza et al, 200936 | SR and MA | KP | Malignant: metastases and multiple myeloma | 2003 to September 2008 | 11/208 | To evaluate the safety and effectiveness of KP for spinal fractures in cancer patients |
| Chew et al, 201137 | SR | VP | Malignant: metastases and multiple myeloma | Inception to April 2010 | 30/760 | To evaluate the efficacy and complications of VP in spinal metastases and multiple myeloma |
| Eck et al, 200838 | SR and MA | VP or KP | Any pathology | Inception to May 15, 2006 | 168/1,036 | To compare pain relief and complication rates between VP and KP |
| Khan et al, 201434 | SR and MA | VP or KP | Multiple myeloma | Inception to June 12, 2012 | 23/154 | To evaluate changes in pain, disability, and analgesic use with vertebral augmentation in multiple myeloma patients |
| Krueger et al, 200939 | SR | VP or KP | Any pathology | Inception to October 2008 | 387/1,222 | To evaluate the incidence and management of pulmonary cement embolism following percutaneous VP or KP |
| Lee et al, 200940 | SR and MA | VP or KP | Any pathology | Inception to December 2006 | 121/NR | To compare complication rates between VP and KP |
| McGirt et al, 200941 | SR | VP or KP | Any pathology | 1980 to 2008 | 127/NR | To evaluate outcomes following VP and KP and rate the evidence |
| Mendel et al, 200933 | SR | VP or KP or embolization | Malignant | To December 15, 2008 | 50/1,665 | To review the safety and effectiveness of VP, KP, or embolization in the treatment of spinal tumours and make recommendations based on the literature and consensus expert opinion |
| Doidge et al, 201142 | SR | VP or KP | Any pathology | 1987 to August 2010 | 183/9,893 | To review the safety, effectiveness, and cost-effectiveness of VP and KP for VCFs |
| Nussbaum et al, 200443 | SR | VP or KP | Any pathology | 1999 to June 27, 2003 | 58 reports | To review the complications reported for VP or KP in the FDA Manufacturer and User Facility Device Experience database (MAUDE) |
| Ehteshami Rad et al, 201244 | SR and MA | VP or KP | Any pathology | Up to March 2010 | 17/1,646 | To review the association between the duration of pre-operative pain and pain improvement in vertebral augmentation |
| Schroeder et al, 201132 | SR | VP or KP | Tumour-related | Up to June 2011 | 2/36 | To compare cement augmentation via VP or KP for spinal fractures caused by tumours, with each other or with other treatment methods |
| Taylor et al, 200645, 200746 | SR and MA | VP or KP | Any pathology | 1983 to March 2004 | 76/487 | To evaluate the safety and effectiveness of KP in patients with VCFs, update the previous review on safety and effectiveness of VP, and examine prognostic factors predicting outcome following the procedures |
Abbreviations: FDA, United States Food and Drug Administration; KP, kyphoplasty; MA, meta-analysis; NR, not reported; SR, systematic review; VCF, vertebral compression fracture; VP, vertebroplasty.